Sign in
Taking peoplePhase 3

Personalized human albumin treatment for people with cirrhosis and fluid build-up in the belly

Tests a personalized albumin approach in adults with advanced cirrhosis and ascites.

Key facts

Who runs it
Odense University Hospital
Where
Leuven, BelgiumSee the siteAlso in 6 other countries, 14 sites
Trial code
Registry title
An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and complications
Status
Recruiting
Phase
Phase 3
People taking part
200 people, planned
Started
29 Mar 2023
Planned end
30 Sept 2026
Type of study
Interventional
Record updated
7 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced liver cirrhosis and fluid build-up in the belly (ascites). They will get long-term human albumin treatment.

Age
18 years or older
Sex
All sexes
Disease stage
Decompensated liver cirrhosis with a Child-Pugh score of 7-12. Ascites seen on exam and/or ultrasound. At least five days since a decompensation event or any hospital stay ended.
Earlier treatment
No TIPS (a shunt in the liver) placed less than 6 months ago. No direct antiviral treatment for HCV in the last six months, now or planned. No previous liver or other transplant.

Main reasons for not taking part

  • Ascites that no longer responds to treatment (refractory ascites)
  • Severe alcoholic hepatitis (Glasgow Alcoholic Hepatitis Score > 11) or hepatic encephalopathy (brain problems from liver disease) grade III-IV
  • Current cancer, except non-melanocytic skin cancer and liver cancer at BCLC-0 or BCLC-A
  • Severe disease of other organs, such as kidney failure needing hemodialysis or severe heart or lung disease
  • HIV positive or weakened immune system, pregnancy or breastfeeding

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Decompensated liver cirrhosis defined as Child-Pugh score 7-12
  • Clinical and/or ultrasound evidenced ascites
  • Age above or equal to 18 years
  • At least five days since resolution of a decompensation event or any condition requiring hospitalization

Who cannot take part

  • Current, planned or previous treatment with direct antiviral agents for HCV in the last six months
  • Participation in another study within 3 months prior to screening
  • Previous liver or other transplantation
  • Patients who decline to participate, patients who cannot provide prior written informed consent due to other causes than hepatic encephalopathy or patients with hepatic encephalopathy who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker or sufficient ability to provide delayed informed consent
  • Patients with acute or subacute liver failure without underlying cirrhosis
  • Portal vein thrombosis without signs of cavernous transformation or recanalization
  • Severe alcoholic hepatitis (Glasgow Alcoholic Hepatitis Score > 11)
  • Evidence of current malignancy except for non-melanocytic skin cancer and hepatocellular carcinoma within BCLC-0 or BCLC-A
  • Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (NYHA above grade II), severe chronic pulmonary disease (GOLD Score above or equal to grade C), severe neurological and psychiatric disorders, pulmonary arterial hypertension)
  • HIV positive or other condition associated with and/or requiring immunosuppression
  • Contraindications for human albumin infusion (pulmonary oedema, hypersensitivity etc.)
  • Refractory ascites as defined by the International Ascites Club
  • Existing TIPS inserted <6 months ago
  • Hepatic encephalopathy grade III-IV
  • Pregnancy
  • Breastfeeding
  • Physician’s denial (investigator considers that the patient will not adhere to the study protocol scheduled, e.g. in case of heavy drinking)
  • Patients with cirrhosis who develop decompensation in the postoperative period following partial hepatectomy

Where in Belgium

Also in 6 other countries, 14 sites

  • Katholieke Universiteit te LeuvenLeuven, BelgiumNo longer taking part

About the trial

What the trial wants to find out

The overall objective is to validate the predictive biomarker of treatment response to human albumin therapy in patients with cirrhosis and ascites

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
ALB-TRIAL: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
Plain-language title
Personalized human albumin treatment for people with cirrhosis and fluid build-up in the bellyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
7 October 2025